Discussion
A global clinical trial testing Ultomiris (ravulizumab-cwvz) in adults with neuromyelitis optica spectrum disorder (NMOSD) found that the treatment kept patients free of relapses for more than 4.5 years. When compared with data from an external group of NMOSD patients given a placebo in a previous trial, the…